Researchers have taken advantage of a rare opportunity to record and map tinnitus in the brain of a patient undergoing surgery, with the goal of finding the brain networks responsible for this condition characterized by "phantom noise."
A UCSF pilot study shows that mindfulness is a treatment approach for tinnitus that may help the roughly 50 million Americans who suffer from the condition, providing longterm relief.
Tinnitus SoundSupport (TSS) encompasses ease of use along with flexibility and variety to promote an uncomplicated fitting process for the audiologist and significant relief for the tinnitus patient.
Oticon introduced its new Inium Sense, a sound processing platform that powers the company's new Alta2, Nera2, and Ria2 hearing aids in its Performance Line of hearing instruments.
A look at the long-term effectiveness of an integrated tinnitus management approach (WZT) and the pattern of therapy use among primary tinnitus patients once successful remediation of symptoms is achieved.
The UK-based charity, Action on Hearing Loss, announced that it is funding a tinnitus study at Newcastle University to help accelerate the development of future tinnitus treatments.
Sanuthera announced that it has submitted its Serenity tinnitus device to the FDA for 510(k) clearance.
Amplisound has announced the release of a new tinnitus device called Quell, which is designed to be used effectively with any tinnitus therapy. While there are many devices available for tinnitus relief, including hearing aids, Quell is particularly suitable for patients who respond specifically to sound therapy and do not want a hearing aid or need amplification.
The results from this clinical study strongly support the use of Widex Zen Therapy in tinnitus patient management. This individualized comprehensive approach combining counseling (instructional and adjustment-based cognitive behavioral intervention), amplification, fractal tones and/or noise, and relaxation strategies was highly effective in reducing tinnitus handicap in a short period of time, with improvements apparent through at least the 6-month duration of this investigation.
The Tinnitus Practitioners Association (TPA) has announced its 3rd Annual International Misophonia Conference, which will be held in Phoenix, Ariz, on February 20-21, 2015.
The AAO-HNS guideline gives healthcare providers a framework for care and support in mitigating the personal and social impact that tinnitus can have. The recommendation includes obtaining a comprehensive audiologic examination and recommendation of sound therapy for patients with persistent bothersome tinnitus.
Audiology Systems and Otometrics is launching a series of new reference materials and training to assist audiologists and other hearing care professionals interested in adding tinnitus treatment to their practice.
The Hearing Review asks three audiologists associated with GN Otometrics and Audiology Systems—Clément Sanchez, AuD, Wendy Switalski, AuD, and Clint Keifer, AuD—for their thoughts on the benefits of tinnitus assessment. They also provide advice to hearing care professionals who are interested in adding tinnitus assessment to their practice.
A look at what the most recent scientific literature says about tinnitus treatment, as well as a review of Cognitive Behavioral Therapy (CBT), Progressive Tinnitus Management (PTM), and Tinnitus Retraining Therapy (TRT).
The results of a randomized, multi-center clinical study published in AJA by Richard Tyler, PhD, and colleagues found SoundCure’s S-Tones® to be effective at quiet volumes and to be more effective than broadband noise in the reduction of tinnitus.
The Levo System from Otoharmonics reportedly leverages the brain's natural cognitive abilities, and identifies and maps an individual's unique sound print using custom-fit ear buds and proprietary software on Apple iPad® and iPod® touch mobile digital devices.
The first clinical trial to investigate the effect of a standardized physical therapy treatment, directed to the cervical spine, on tinnitus is being conducted at the University of Antwerp.
Auris Medical Holding AG —the developer of treatments for acute inner ear tinnitus (AM-101) and acute inner ear hearing loss (AM-111) by way of intratympanic injection—announced on August 6 pricing of its IPO. The company's common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol “EARS”.
Loyola University surgeon says athletes who play football and other contact sports may be at risk for hearing damage and tinnitus.
Patients with tinnitus process emotions differently in the brain from those with normal hearing, researchers report in the journal Brain Research.